The emerging role of circulating microRNAs as biomarkers in autoimmune diseases

Zeng, Li; Cui, Juncheng; Wu, Haijing; Lu, Qianjin

doi:10.3109/08916934.2014.929667

Cited by 63 publications

(46 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,25 Their stability, along with the development of sensitive methods for their detection and quantification, 20 makes circulating miRNAs as ideal candidates for biomarkers. Investigators have identified changes in circulating miRNAs in a number of disease processes (reviewed in references 26–28) and we previously reported changes in circulating plasma miRNAs in patients with MS. 29 In the present study, we investigated serum miRNAs in MS as part of the NIH common fund UH2 initiative. We found that several serum miRNAs are differentially expressed in MS, associate with disease stage, and correlate with disability.…”

mentioning

confidence: 91%

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis

Regev

Paul

Healy³

et al. 2016

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Objective:To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS).Methods:Sera from 296 participants including patients with MS, other neurologic diseases (Alzheimer disease and amyotrophic lateral sclerosis), and inflammatory diseases (rheumatoid arthritis and asthma) and healthy controls (HCs) were tested. miRNA profiles were determined using LNA (locked nucleic acid)-based quantitative PCR. Patients with MS were categorized according to disease stage and disability. In the discovery phase, 652 miRNAs were measured in sera from 26 patients with MS and 20 HCs. Following this, significant miRNAs (p < 0.05) from the discovery set were validated using quantitative PCR in 58 patients with MS, 30 HCs, and in 74 samples from other disease controls (Alzheimer disease, amyotrophic lateral sclerosis, asthma, and rheumatoid arthritis).Results:We validated 7 miRNAs that differentiate patients with MS from HCs (p < 0.05 in both the discovery and validation phase); miR-320a upregulation was the most significantly changing serum miRNA in patients with MS. We also identified 2 miRNAs linked to disease progression, with miR-27a-3p being the most significant. Ten miRNAs correlated with the Expanded Disability Status Scale of which miR.199a.5p had the strongest correlation with disability. Of the 15 unique miRNAs we identified in the different group comparisons, 12 have previously been reported to be associated with MS but not in serum.Conclusions:Our findings identify circulating serum miRNAs as potential biomarkers to diagnose and monitor disease status in MS.Classification of evidence:This study provides Class III evidence that circulating serum miRNAs can be used as biomarker for MS.

show abstract

mentioning

confidence: 91%

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis

Regev

Paul

Healy³

et al. 2016

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

show abstract

“…MiRNAs are important regulators of both genes and pathways of immune cells including proliferation, differentiation, and apoptosis [30]. Furthermore, dysregulated miRNA expression is associated with autoimmunity and inflammation [31,32].…”

Section: Epigenetic Mechanismsmentioning

confidence: 99%

Epigenetics and Vasculitis: a Comprehensive Review

Renauer

Coit

Sawalha

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Vasculitides represent a group of relatively rare systemic inflammatory diseases of the blood vessels. Despite recent progress in understanding the genetic basis and the underlying pathogenic mechanisms in vasculitis, the etiology and pathogenesis of vasculitis remain incompletely understood. Epigenetic dysregulation plays an important role in immune-mediated diseases, and the contribution of epigenetic aberrancies in vasculitis is increasingly being recognized. Histone modifications in the PR3 and MPO gene loci might be mechanistically involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Similarly, other studies revealed important epigenetic contribution to other vasculitides, including Kawasaki disease and IgA vasculitis. More recently, genome-wide epigenomic studies have been performed in several vasculitides. A recent genome-wide DNA methylation study uncovered an important role for epigenetic remodeling of cytoskeleton-related genes in the pathogenesis of Behçet's disease and suggested that reversal of some of these DNA methylation changes associates with disease remission. Genome-wide DNA methylation profiling characterized the inflammatory response in temporal artery tissue from patients with giant cell arteritis and showed increased activation of calcineurin/nuclear factor of activated T cells (NFAT) signaling, prompting the suggestion that a specific calcineurin/NFAT inhibitor that is well tolerated and with the added beneficial anti-platelet activity, such as dipyridamole, might be of therapeutic potential in giant cell arteritis. While epigenetic studies in systemic vasculitis are still in their infancy, currently available data clearly indicate that investigating the epigenetic mechanisms underlying these diseases will help to better understand the pathogenesis of vasculitis and provide novel targets for the development of disease biomarkers and new therapies.

show abstract

“…In latent EBV infections involving host functional immunity, EBV expresses limited levels of protein but high levels of noncoding RNAs, including miRNAs. This indicates that the miRNAs are related to viral immune evasion (Jia et al, 2014;Zeng et al, 2014). EBV expresses about 40 mature miRNAs that target viral or cellular genes to induce different functions.…”

Section: Introductionmentioning

confidence: 99%

An update: Epstein-Barr virus and immune evasion via microRNA regulation

Zuo

Yue

et al. 2017

Virol. Sin.

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is an oncogenic virus that ubiquitously establishes life-long persistence in humans.To ensure its survival and maintain its B cell transformation function, EBV has developed powerful strategies to evade host immune responses. Emerging evidence has shown that microRNAs (miRNAs) are powerful regulators of the maintenance of cellular homeostasis. In this review, we summarize current progress on how EBV utilizes miRNAs for immune evasion. EBV encodes miRNAs targeting both viral and host genes involved in the immune response. The miRNAs are found in two gene clusters, and recent studies have demonstrated that lack of these clusters increases the CD4 + and CD8 + T cell response of infected cells. These reports strongly indicate that EBV miRNAs are critical for immune evasion. In addition, EBV is able to dysregulate the expression of a variety of host miRNAs, which influence multiple immune-related molecules and signaling pathways. The transport via exosomes of EBV-regulated miRNAs and viral proteins contributes to the construction and modification of the inflammatory tumor microenvironment. During EBV immune evasion, viral proteins, immune cells, chemokines, pro-inflammatory cytokines, and pro-apoptosis molecules are involved. Our increasing knowledge of the role of miRNAs in immune evasion will improve the understanding of EBV persistence and help to develop new treatments for EBV-associated cancers and other diseases.

show abstract

The emerging role of circulating microRNAs as biomarkers in autoimmune diseases

Cited by 63 publications

References 103 publications

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis

Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis

Epigenetics and Vasculitis: a Comprehensive Review

An update: Epstein-Barr virus and immune evasion via microRNA regulation

Contact Info

Product

Resources

About